87.20
Soleno Therapeutics Inc stock is traded at $87.20, with a volume of 1.19M.
It is down -0.50% in the last 24 hours and up +9.85% over the past month.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
See More
Previous Close:
$87.64
Open:
$88.25
24h Volume:
1.19M
Relative Volume:
1.13
Market Cap:
$4.39B
Revenue:
-
Net Income/Loss:
$-38.99M
P/E Ratio:
-29.10
EPS:
-2.9966
Net Cash Flow:
$-24.94M
1W Performance:
+6.91%
1M Performance:
+9.85%
6M Performance:
+86.01%
1Y Performance:
+87.97%
Soleno Therapeutics Inc Stock (SLNO) Company Profile
Name
Soleno Therapeutics Inc
Sector
Industry
Phone
650-213-8444
Address
100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA
Compare SLNO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
SLNO
Soleno Therapeutics Inc
|
87.20 | 4.30B | 0 | -38.99M | -24.94M | -2.9966 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Soleno Therapeutics Inc Stock (SLNO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jun-23-25 | Initiated | TD Cowen | Buy |
Mar-05-25 | Resumed | Stifel | Buy |
Dec-02-24 | Reiterated | Robert W. Baird | Outperform |
Dec-02-24 | Reiterated | Stifel | Buy |
Sep-03-24 | Initiated | H.C. Wainwright | Buy |
May-10-24 | Initiated | Robert W. Baird | Outperform |
Feb-05-24 | Initiated | Piper Sandler | Overweight |
Jan-23-24 | Initiated | Stifel | Buy |
Nov-21-23 | Resumed | Guggenheim | Buy |
Sep-29-20 | Initiated | Guggenheim | Buy |
Jan-10-20 | Initiated | Craig Hallum | Buy |
Dec-23-19 | Initiated | Oppenheimer | Outperform |
Feb-13-18 | Reiterated | Maxim Group | Buy |
View All
Soleno Therapeutics Inc Stock (SLNO) Latest News
What analysts say about Soleno Therapeutics Inc. stockPhenomenal investment performance - Autocar Professional
Soleno gains as Betaville cites buyout interest (update) - MSN
Soleno Therapeutics Inc. Stock Analysis and ForecastConsistent triple-digit returns - Jammu Links News
Is Soleno Therapeutics Inc. a good long term investmentHigh-profit capital plays - Jammu Links News
(SLNO) Trading Report - news.stocktradersdaily.com
Soleno Therapeutics: A Strategic Capital Raise Balances M&A Optionality with Long-Term Growth Potential - AInvest
Soleno Therapeutics: Fairly Valued Despite M&A Expectations - Seeking Alpha
Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer - The Globe and Mail
Mintz Advises on Soleno Therapeutics’ $200 Million Public Offering - Mintz
Soleno Therapeutics Shares Dip Following $200 Million Stock Offering Pricing - MSN
Soleno Therapeutics stock dips on proposed $200M offering - MSN
Baird Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Raises Target Price to $121 - 富途牛牛
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch - Investing.com Nigeria
Stifel reiterates Buy rating on Soleno Therapeutics stock amid strong Vykat launch By Investing.com - Investing.com South Africa
Soleno Therapeutics Announces Public Stock Offering - TipRanks
In Brief: Soleno To Raise $200m To Boost Vykat XR Launch - insights.citeline.com
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales - Investing.com Australia
Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock - GlobeNewswire
Baird raises Soleno Therapeutics stock price target to $121 on strong Vykat XR sales - Investing.com Nigeria
Firm Advises Soleno Therapeutics on $200 Million Public Offering - Wilson Sonsini
Soleno reports preliminary Q2 revenue of $31-33 million for VYKAT XR - Investing.com Nigeria
Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock - GlobeNewswire
Soleno sales of new Prader-Willi drug rise faster than expected - BioPharma Dive
Soleno Therapeutics Prices $200 Mln Public Offering To Support VYKAT XR Launch - Nasdaq
Soleno Therapeutics stock falls after pricing $200 million offering By Investing.com - Investing.com Canada
Soleno Therapeutics stock falls after pricing $200 million offering - Investing.com
Soleno Therapeutics prices public offering at $85 per share - Investing.com
Soleno Therapeutics prices public offering at $85 per share By Investing.com - Investing.com South Africa
Soleno Therapeutics prices $200M public offering - MSN
Soleno Therapeutics Secures $200M Public Offering to Commercialize Breakthrough Prader-Willi Treatment - Stock Titan
Soleno Therapeutics stock soars as Stifel reiterates Buy on strong Vykat sales By Investing.com - Investing.com South Africa
Soleno Therapeutics: Q2 2025 Results Signal Breakout Potential in Rare Disease Market - AInvest
Soleno Therapeutics announces preliminary financial and operational results for Q2 - MarketScreener
Soleno Therapeutics' $200M Secondary Offering: Catalyst for Growth or Dilution Danger Zone? - AInvest
Soleno Therapeutics Reports Q2 Preliminary Net Revenue - MarketScreener
Soleno Therapeutics Proposes $200 Million Public Offering - MarketScreener
Soleno Therapeutics Reports Preliminary Financial Results for Q2 2025, Anticipating $31-$33 Million in Revenue from VYKAT™ XR - Nasdaq
Soleno Therapeutics Announces Preliminary Financial and - GlobeNewswire
Soleno's New Drug VYKAT XR Hits $33M Revenue in First Quarter Launch with Nearly 300 Prescribers - Stock Titan
Soleno Therapeutics (SLNO) Soars 5.93% on Regulatory Milestone - AInvest
Analysts Offer Insights on Healthcare Companies: Merit Medical Systems (MMSI) and Soleno Therapeutics (SLNO) - The Globe and Mail
Soleno Therapeutics stock price target raised to $115 by Stifel on strong Vykat demand - Investing.com South Africa
Soleno Therapeutics stock poised for success as Piper Sandler sees $2B+ potential - Investing.com Nigeria
(SLNO) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Soleno Therapeutics stock price target raised to $115 from $108 at Stifel - Investing.com Nigeria
Soleno Therapeutics stock price target raised to $115 from $108 at Stifel By Investing.com - Investing.com South Africa
Soleno Therapeutics stock poised for success as Piper Sandler sees $2B+ potential By Investing.com - Investing.com South Africa
Soleno Therapeutics Inc Stock (SLNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):